{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:38Z","timestamp":1792601018056,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dsx.2024.103116","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:12:51Z","timestamp":1726737171000},"page":"103116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-9562","authenticated-orcid":false,"given":"Mahmoud","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abosheaishaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dsx.2024.103116_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.04.012","article-title":"Factors that affect disease progression after first attack of acute pancreatitis","volume":"13","author":"Bertilsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.dsx.2024.103116_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.5152\/tjg.2020.20775","article-title":"Risk factors of recurrence of acute pancreatitis: a retrospective research","volume":"32","author":"Song","year":"2021","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dsx.2024.103116_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archsurg.1979.01370300065010","article-title":"Predictability of present outcome and future recurrence in acute pancreatitis","volume":"114","author":"Satiani","year":"1979","journal-title":"Arch Surg"},{"issue":"11 Suppl","key":"10.1016\/j.dsx.2024.103116_bib4","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.cgh.2009.08.022","article-title":"Long-term prognosis of acute pancreatitis in Japan","volume":"7","author":"Takeyama","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"47","key":"10.1016\/j.dsx.2024.103116_bib5","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.3748\/wjg.v23.i47.8387","article-title":"Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis","volume":"23","author":"Xiang","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dsx.2024.103116_bib6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.gastro.2008.11.044","article-title":"The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial","volume":"136","author":"Nordback","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dsx.2024.103116_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00365521.2019.1699598","article-title":"Risk factors of recurrent pancreatitis after first acute pancreatitis attack: a retrospective cohort study","volume":"55","author":"Cho","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2024.103116_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Therapeut"},{"issue":"3","key":"10.1016\/j.dsx.2024.103116_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14740338.2018.1428305","article-title":"A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment","volume":"17","author":"Consoli","year":"2018","journal-title":"Expet Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.dsx.2024.103116_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13300-017-0230-2","article-title":"Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naive patients with type 2 diabetes mellitus: a multinational preference study","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.dsx.2024.103116_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.2015.987122","article-title":"Potential side effects to GLP-1 agonists: understanding their safety and tolerability","volume":"14","author":"Consoli","year":"2015","journal-title":"Expet Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.dsx.2024.103116_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4239\/wjd.v15.i2.133","article-title":"Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: a new horizon","volume":"15","author":"Nassar","year":"2024","journal-title":"World J Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2024.103116_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13547","article-title":"Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: a retrospective comparative effectiveness study based on a global TriNetX health research database","volume":"16","author":"Nassar","year":"2024","journal-title":"J Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.dsx.2024.103116_bib14","doi-asserted-by":"crossref","first-page":"A426","DOI":"10.1210\/jendso\/bvac150.887","article-title":"RF28 | PSUN182 risk of pancreatitis after glp-1 receptor agonist in individuals with known history of pancreatitis","volume":"6","author":"Kodali","year":"2022","journal-title":"Journal of the Endocrine Society"},{"issue":"6","key":"10.1016\/j.dsx.2024.103116_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.dsx.2024.103116_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.dsx.2024.103116_bib17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc13-2983","article-title":"Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study","volume":"38","author":"Thomsen","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2024.103116_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.dsx.2024.103116_bib19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.dsx.2024.103116_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dsx.2024.103116_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2024.103116_bib22","doi-asserted-by":"crossref","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.dsx.2024.103116_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","author":"Fink-Jensen","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.dsx.2024.103116_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2019.01.033","article-title":"Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: an integrative review","volume":"149","author":"Yammine","year":"2019","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:17:07Z","timestamp":1733131027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402124001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1871402124001772"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103116","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103116"}}